CAR-T Cell Therapy Market

Access full Research:

https://www.renub.com/car-t-cell-therapy-market-p.php

CAR-T Cell therapy market is expected to grow with a CAGR of over 46 percent in the forecast period. Year 2017 has created new milestone for the oncology patients as FDA approved the first two CD19-targeted (Chimeric Antigen Receptor) CAR-T cell therapies developed by Novartis and Gilead Sciences/Kite Pharma in the United States. These two approvals will certainly help to boost the global CAR-T cell therapy market as more players are looking this big opportunities to enter the market place. At present over 200 CAR-T clinical trials are running or completed across various parts of the world.

Rising number of adults and children developing cancer, increasing government initiatives for promoting research for cell therapy in cancer and rising number of clinical trials globally are some of the key drivers for the global CAR-T Cell therapy market; however high cost of CAR-T cell therapy treatment and regulatory challenges are key inhibitors for this market.